Amgen Dedicates Longmont Manufacturing Facility.LONGMONT, Colo.--(BUSINESS WIRE)--Oct. 1, 1999-- Amgen (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :AMGN) today dedicated its state-of-the-art Longmont Manufacturing Facility which will initially be used for the production of Epoetin alfa e·po·e·tin al·fa n. A recombinant preparation of human erythropoietin used to treat some forms of anemia. epoetin alfa Epogen, Eprex (CA) (UK), Procrit Pharmacologic class: , a recombinant version of a protein used to treat dialysis patients who suffer from anemia associated with kidney failure kidney failure or renal failure Partial or complete loss of kidney function. Acute failure causes reduced urine output and blood chemical imbalance, including uremia. Most patients recover within six weeks. . Amgen sells Epoetin alfa as EPOGEN(R) in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. . EPOGEN, which received approval for marketing from the Food and Drug Administration in 1989, will be just one of the therapeutics manufactured at the site using mammalian cell lines. "The dedication of the Longmont Manufacturing Facility is the culmination of three years of work by Amgen people and the many contractors working on this project. It is a significant milestone in Amgen's transition to a multi-product company," said Gordon Binder Gordon Binder is currently managing director of Coastview Capital, LLC, and previously was chairman of Amgen[1]. He joined Amgen in 1982, and previously had executive roles at the United Geophysical Corporation and the System Development Corporation. , chairman and chief executive officer. Faced with increasing demand beyond the capacity of its existing manufacturing facility, Amgen made the decision in 1995 to build a new plant to increase capacity for Epoetin alfa. The site is comprised of four buildings including a central utility plant, a 110,000 square-foot laboratory and support building, a 110,000 square-foot warehouse and a 194,000 square-foot manufacturing facility. This facility will ultimately have three times the Epoetin alfa production capacity of Amgen's California plant located at the Thousand Oaks Thousand Oaks, residential city (1990 pop. 104,352), Ventura co., S Calif., in a farm area; inc. 1964. Avocados, citrus, vegetables, strawberries, and nursery products are grown. home office. "Amgen chose Longmont for the site of its manufacturing plant because of its close proximity to existing manufacturing plants in Boulder and its very supportive business environment," said Dennis Fenton, senior vice president, Operations. "We are looking forward to continuing to build relationships in the community and grow in an environment which provides a great quality of life for our staff." Amgen's current Colorado operations occupy nine buildings and employ nearly 450 staff. The Company anticipates that approximately 225 staff will be working in Longmont by year end. Amgen is a global biotechnology company that discovers, develops, manufactures and markets cost-effective human therapeutics based on advances in cellular and molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller . |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion